PERK modulation, with GSK2606414, Sephin1 or salubrinal, failed to produce therapeutic benefits in the SOD1G93A mouse model of ALS

• Fernando G. Vieira,

  Roles Conceptualization, Funding acquisition, Project administration, Resources, Writing – review & editing

  Affiliation ALS Therapy Development Institute, Watertown, MA, United States of America

  ⨯
• Valerie R. Tassinari,

  Roles Investigation, Methodology

  Affiliation ALS Therapy Development Institute, Watertown, MA, United States of America

  ⨯
• Joshua D. Kidd,

  Roles Methodology

  Affiliation ALS Therapy Development Institute, Watertown, MA, United States of America

  ⨯
• Andrew Moreno,

  Roles Methodology

  Affiliation ALS Therapy Development Institute, Watertown, MA, United States of America

  ⨯
• Kenneth Thompson,

  Roles Methodology, Resources

  Affiliation ALS Therapy Development Institute, Watertown, MA, United States of America

  ⨯
• Steven Perrin,

  Roles Conceptualization, Funding acquisition, Supervision

  Affiliation ALS Therapy Development Institute, Watertown, MA, United States of America

  ⨯
• Alan Gill,

  Roles Conceptualization, Data curation, Formal analysis, Visualization, Writing – review & editing

  Affiliation ALS Therapy Development Institute, Watertown, MA, United States of America

  ⨯
• Theo Hatzipetros

  Roles Conceptualization, Data curation, Formal analysis, Project administration, Supervision, Visualization, Writing – original draft, Writing – review & editing

  * E-mail: thatzipetros@als.net

  Affiliation ALS Therapy Development Institute, Watertown, MA, United States of America

  https://orcid.org/0009-0008-0876-2460

  ⨯